Artículos de revistas
Therapeutic effects of Salmonella Typhi in a mouse model of T-cell lymphoma
Fecha
2013-04Registro en:
Vendrell, Alejandrina; Gravisaco, María J.; Goin, Juan Carlos; Pasetti, Marcela F.; Herschllik, Leticia; et al.; Therapeutic effects of Salmonella Typhi in a mouse model of T-cell lymphoma; Lippincott Williams; Journal Of Immunotherapy; 36; 3; 4-2013; 171-180
1524-9557
Autor
Vendrell, Alejandrina
Gravisaco, María J.
Goin, Juan Carlos
Pasetti, Marcela F.
Herschllik, Leticia
de Toro, Julieta
Rodriguez, Carla Andrea
Larotonda, Gerardo
Mongini, Claudia
Waldner, Claudia Ines
Resumen
In this study, we assessed the effectiveness of a live, attenuated Salmonella enterica serovar Typhi (S. Typhi) vaccine strain as a cancer immunotherapy in a mouse model of metastatic T-cell lymphoma. EL4 tumor-bearing C57BL/6J mice immunized with S. Typhi strain CVD 915, by injection into the tumor and the draining lymph node areas, displayed a significant decrease in tumor growth, a reduction in the mitotic index (MI) of tumors, a delayed development of palpable lymph node metastases and most importantly improved survival, compared to untreated mice. Besides, complete tumor regression was achieved in a small number of bacteria-treated mice. A successful therapeutic response associated with a significant reduction of tumor mass was evident as early as 5 days after treatment. The administration of Salmonella to tumor-bearing mice promoted early cellular infiltration (mainly neutrophils) within the tumor, and was accompanied by a decreased intratumoral interleukin 10 production as well as by leukocyte expansion in tumor draining lymph nodes. A tumor-specific memory immune response was induced in most of cured animals, as evidenced by the lack of tumor growth after a rechallenge with the same tumor. EL4 cells cultured with live Salmonella failed to proliferate and underwent apoptosis in a dose-dependent, timedependent, and contact-dependent manner. To our knowledge, these results demonstrate for the first time the efficacy of a S. Typhi vaccine strain as an oncolytic and immunotherapeutic agent against a highly malignant tumor and support the use of S. Typhi-based vaccine strains in cancer therapy.